Sanofi (NASDAQ: SNY, Euronext Paris: SAN)’s amlitelimab still looks like a viable U.S. approval candidate, but it is no longer the clear successor to Dupixent that investors once hoped for. The latest data keeps the program alive from a regulatory standpoint, yet introduces enough uncertainty that the stock is unlikely to move meaningfully on this drug alone.
Put simply, amlitelimab remains an option on future value rather than a near-term growth driver.
Why This Matters for Sanofi
Dupixent has been a cornerstone product for Sanofi, generating more than €11 billion, or about $13 billion, in sales across approved indications. With patent protection ending in 2031, management needs credible pipeline assets to support the immunology franchise beyond that point.
Amlitelimab was acquired through Sanofi’s $1.1 billion purchase of Kymab in 2021 and was intended to help fill that gap. The investment was based on the drug’s different biology and the potential for less frequent dosing. That thesis has not fallen apart, but it also has not improved with the latest data.
What the New Data Shows
The update includes results from two Phase 3 trials, SHORE and COAST 2, along with a Phase 2 safety study called ATLANTIS. One of the Phase 3 studies produced clean results, while the other did not meet regulatory expectations in Europe.
In SHORE, patients treated with amlitelimab were more likely than placebo recipients to achieve clear or nearly clear skin and to see meaningful reductions in disease severity. These are outcomes that align well with U.S. regulatory standards.
In COAST 2, the drug showed numerical improvement over placebo, but European regulators apply a different method for counting non-responders. Under that framework, the trial missed the required statistical threshold, even though response rates favored amlitelimab.
Sanofi plans to pursue regulatory submissions based on the combined data package. That approach is more likely to succeed in the U.S. than in Europe.
Safety Considerations
The ATLANTIS safety study delivered a mixed picture. On the positive side, patients continued to improve over time, with no clear loss of efficacy after a year of treatment. That supports the idea that the drug could be used long term.
At the same time, a case of Kaposi’s sarcoma was reported in a patient receiving amlitelimab. Even if the event proves to be rare or unrelated, it introduces risk. Regulators may take a closer look, and any additional warning language could slow uptake after approval.
This does not end the program, but it limits how aggressively investors are likely to value it.
Competitive Landscape
Amlitelimab targets the OX40L pathway, an area that once attracted significant interest. That enthusiasm has cooled following weaker data from other companies, including Amgen. As a result, expectations for this class of drugs are more modest.
Without clear best-in-class efficacy, amlitelimab will need to compete on factors such as dosing convenience and tolerability, which tend to support steady adoption rather than rapid market share gains.
What to Watch Next
Two additional Phase 3 trials are still ongoing, with results expected later this year. Those data will be important in determining whether amlitelimab becomes a meaningful commercial product or remains a secondary pipeline asset.
Until those results are available, investor sentiment is likely to remain cautious.
Bottom Line
Amlitelimab is likely good enough to support a U.S. regulatory filing and could reach the market. However, it does not materially change the long-term investment case for Sanofi on its own.
For investors, the drug represents optional upside rather than a reason to revalue the stock. The core story continues to rest on Dupixent’s durability and Sanofi’s ability to rebuild its immunology pipeline ahead of patent expiration.
Progress has been made, but this is not a defining catalyst.
